Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France

References

• Le ChevalierTAdjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going?Ann Oncol201021suppl 7vii196vii19820943614
   PubMed Web of Science ®Google Scholar
• BoylePFerlayJCancer incidence and mortality in Europe, 2004Ann Oncol200516348148815718248
   PubMed Web of Science ®Google Scholar
• American Cancer SocietyDetailed Guide: Lung Cancer (Non-Small Cell)2017 [cited October 6, 2017]. Available from: https://www.cancer.org/cancer/non-small-cell-lung-cancer.htmlAccessed October 6, 2017
   Google Scholar
• LeighlNBTreatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-lineCurr Oncol201219suppl 1S52S5822787411
   PubMed Web of Science ®Google Scholar
• Cancer ResearchUKLung Cancer Survival Statistics2016 [cited October 4, 2016]. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer/survivalAccessed October 4, 2016
   Google Scholar
• RizviNAHellmannMDBrahmerJRNivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancerJ Clin Oncol201634252969297927354481
   PubMed Web of Science ®Google Scholar
• CalikusuZYildirimYAkcaliZThe effect of HER2 expression on cisplatin-based chemotherapy in advanced non-small cell lung cancer patientsJ Exp Clin Cancer Res2009289719575783
   PubMed Web of Science ®Google Scholar
• Consensus GuidelinesESMONon-Small-Cell Lung Cancer First-Line/Second and Further Lines in Advanced Disease2014 [cited October 4, 2016]. Available from: http://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/Consensus-Guidelines-Non-small-cell-lung-cancer-first-line-second-and-further-lines-in-advanced-diseaseAccessed October 4, 2016
   Google Scholar
• HoelzerDBassanRDombretHAcute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201627suppl 5v69v8227056999
   PubMed Web of Science ®Google Scholar
• ShuCARizviNAInto the clinic with nivolumab and pembrolizumabOncologist20162152752827026678
   PubMed Web of Science ®Google Scholar
• RizviNAMazièresJPlanchardDActivity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trialLancet Oncol20151625726525704439
   PubMed Web of Science ®Google Scholar
• GaronEBRizviNAHuiRPembrolizumab for the treatment of non-small-cell lung cancerN Engl J Med2015372212018202825891174
   PubMed Web of Science ®Google Scholar
• HerbstRSBaasPKimDWPembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialLancet2016387100271540155026712084
   PubMed Web of Science ®Google Scholar
• SequistLVYangJCYamamotoNPhase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutationsJ Clin Oncol201331273327333423816960
   PubMed Web of Science ®Google Scholar
• WuYLZhouCHuCPAfatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trialLancet Oncol201415221322224439929
   PubMed Web of Science ®Google Scholar
• SoriaJ-CFelipECoboMAfatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trialLancet Oncol201516889790726156651
   PubMed Web of Science ®Google Scholar
• ModjtahediHChoBCMichelMCSolcaFA comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancerNaunyn Schmiedebergs Arch Pharmacol2014387650552124643470
   PubMed Web of Science ®Google Scholar
• HirshVNext-generation covalent irreversible kinase inhibitors in NSCLC: focus on afatinibBioDrugs201529316718326123538
   PubMed Web of Science ®Google Scholar
• Kantar Health Database [cited January 1, 2017]. Available from: http://www.kantarhealth.com/services/epidemiologyAccessed January 1, 2017
   Google Scholar
• Technical Agency for Information on Hospitalization (ATIH)Analysis of hospital activity 20152015 [cited February 24, 2017]. Available from http://www.atih.sante.fr/sites/default/files/public/content/3020/atih_synthese_activite_hospitaliere_2015_0.pdfAccessed October 10, 2017 French
   Google Scholar
• Court of AuditSocial Insurance 2012. Patient transports reimbursed by healthcare insurance2012 [cited October 5, 2016]. Available from: https://www.ccomptes.fr/fr/documents/23069 Cited September 13, 2012Accessed October 6, 2017 French
   Google Scholar
• National Healthcare Insurance for Employees (CNAMTS)National table for diagnostic codes2016 [cited October 5, 2016]. Available from: http://www.codage.ext.cnamts.fr/codif/nabm/index.php?p_site=AMELIAccessed October 6, 2017 French
   Google Scholar
• National Healthcare Insurance Online (AMELI)General nomenclature for professional procedures (NGAP) Version dated March 11, 2015 [cited October 5, 2016. Available from: http://www.ameli.fr/professionnels-de-sante/directeurs-d-etablissements-de-sante/codage/ngap.phpAccessed October 6, 2017 French
   Google Scholar
• Ameli.frNomenclature générale des actes professionnels – NGAP Version dated March 11, 2015 [cited October 5, 2016]. Available from: http://www.ameli.fr/professionnels-de-sante/directeurs-d-etablissements-de-sante/codage/ngap.phpAccessed October 6, 2017
   Google Scholar
• BanzKBischoffHBrunnerMComparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and SpainLung Cancer201174352953421592611
   PubMed Web of Science ®Google Scholar
• ChevalierJde PouvourvilleGValuing EQ-5D using time trade-off in FranceEur J Health Econ2013141576621935715
   PubMed Web of Science ®Google Scholar
• NafeesBStaffordMGavrielSBhallaSWatkinsJHealth state utilities for non small cell lung cancerHealth Qual Life Outcomes200868418939982
   PubMed Web of Science ®Google Scholar
• MonnetIAudigier-ValetteCGirardNReal-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: results of the PEPiTA observational studyLung Cancer201698849027393512
   PubMed Web of Science ®Google Scholar
• LiNYangLOuWZhangLZhangSLWangSYMeta-analysis of EGFR tyrosine kinase inhibitors compared with chemotherapy as second-line treatment in pretreated advanced non-small cell lung cancerPLoS One20149e10277725029199
   PubMed Web of Science ®Google Scholar